Blog
The Forecast Is Dead: Why Decision Latency Is the Clinical Supply Metric That Matters
Chris Driver, Senior Director, Product Management, AI & Technology Solutions, Patient Suite
Nov 17, 2026

Every clinical supply forecast is already wrong.

Mine included.

That statement may sound provocative, but it reflects a simple reality: a forecast captures conditions at a moment in time. The study keeps moving.

Enrollment accelerates at some sites and slows at others. Patients visit outside expected windows. Investigational product approaches expiry. Supply routes change. New risks emerge.

A forecast remains an important planning tool, but it cannot keep pace with every change that occurs once a study is underway.

That is why I believe clinical supply organizations need to focus on a different metric: decision latency, or the time between recognizing a change and taking action.

A forecast is a photograph of a moving object

For decades, the industry has worked to improve forecast accuracy. Forecasts help organizations anticipate demand, establish supply strategies, and plan operations.

But no matter how sophisticated the forecast, reality eventually diverges from the plan.

The challenge is not that the forecast was wrong.

The challenge is how quickly an organization responds once conditions change.

Too often, new signals wait for the next planning cycle, the next review meeting, or the next escalation before they become decisions.

Meanwhile, the study continues moving.

The metric that matters

Consider an enrollment surge at several sites.

In a traditional planning-cycle model, the change may not become visible until the next scheduled review. Teams align on a response, approvals are secured, and additional supply is moved.

The response may be appropriate, but valuable time has been lost.

In a continuously monitored environment, that same signal can be evaluated in hours rather than weeks. Site-level triggers can be adjusted, inventory can be reassessed, and actions can occur before the issue develops into a larger operational challenge.

The study is the same.

The people are the same.

The signal is the same.

The difference is how long the signal waits.

What clinical supply professionals told us

At a recent CTS West session, I asked attendees how their organizations make supply decisions today.

Nearly two-thirds reported relying primarily on periodic forecast cycles. Yet when presented with enrollment, expiry, and patient-scheduling challenges, attendees consistently selected targeted, risk-based responses rather than broad study-wide actions.

The scenarios were designed for the interactive session and should not be interpreted as formal industry research. Still, the exercise highlighted an important reality.

The industry increasingly thinks dynamically.

Its operating model has not always caught up.

People still set the rules

When discussing automation, one question comes up consistently: Who remains in control?

The answer is simple: people do.

Supply teams establish the strategy, define the guardrails, and determine when human intervention is required. Actions remain parameterized, auditable, and reversible, with exceptions routed to people rather than automated systems.

The objective is not to replace experienced supply professionals.

It is to apply their expertise at a scale and frequency that would be difficult to achieve manually.

Precision changes the equation

Clinical supply decisions are often framed as trade-offs.

More inventory reduces risk. Fewer shipments increase risk. Greater patient protection requires greater cost.

But results from real, anonymized studies suggest the equation may be changing.

One global study reported 73% fewer shipments, 76% fewer stockouts, more than $1 million in annual savings, and over 16,000 automated supply decisions. Portfolio results across 43 studies showed site-level wastage reduced from 31% to 13% of kits shipped to sites.*

These outcomes suggest that greater precision can improve efficiency and patient protection simultaneously.

Beyond the forecast

Forecasts will remain an important part of clinical supply planning.

But a forecast was never meant to be the operating model.

As studies become more dynamic, success depends less on predicting perfectly and more on responding quickly when reality inevitably diverges from the plan.

The organizations that thrive will not be the ones with the most accurate forecast.

They will be the ones that can adapt fastest.

The forecast is dead. What replaces it is already running.

 

*The presentation identifies IQVIA IRT's Supply Automation Value Engine as the source and notes the sponsors were anonymized.

Chris Driver

Senior Director, Product Management, AI & Technology Solutions, Patient Suite

With over two decades in the clinical technology space, Chris brings a wealth of expertise across Product, R&D and Information Technology functions. Chris leverages a deep understanding of the patient, site and sponsor experience to drive innovation and excellence in clinical research solutions. With a particular focus on product innovation and the development of global health platforms, Chris's passion for innovative healthcare technology is driven by a vision for a future where patient care is both personalized and accessible.

Related solutions